Can we cut back on bladder drugs for seniors? new study aims to find out

NCT ID NCT06110975

Ongoing Knowledge-focused Sponsor: Anne Estrup Olesen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a guideline designed to help doctors safely reduce or stop overactive bladder medications in people aged 65 and older. Researchers will compare how many patients continue these drugs after six months between those whose doctors follow the guideline and those who receive usual care. The goal is to see if deprescribing can be done effectively in general practice without harming patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: deprescribing guideline (procedure)
What this could lead to: If successful, this could provide a safe way to reduce unnecessary medications for overactive bladder in older adults, improving quality of life and reducing side effects.
What could go wrong: This is a small, early-stage study (72 participants) testing a process, not a new drug. The approach may not work for everyone or may not be adopted widely in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESCRIBING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19–associated multisystem inflammatory syndrome in children overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESCRIBING OVERACTIVE BLADDER PIMS

Contacts and locations

Locations

Aalborg University Hospital

Aalborg, Aalborg, 9000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.